Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD79B

CD79B

Brief Information

Name:B-cell antigen receptor complex-associated protein beta chain
Target Synonym:B-Cell Antigen Receptor Complex-Associated Protein Beta Chain,B29,Immunoglobulin-associated B29 protein,Ig-beta,B-cell-specific glycoprotein B29,CD79B,CD79b Molecule,CD79b Molecule, Immunoglobulin-Associated Beta,IGB,CD79B Antigen (Immunoglobulin-Associated Beta),CD79b Antigen,AGM6
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CDB-H82E3-ELISA
 CD79B ELISA

Immobilized Biotinylated Human CD79B, His,Avitag (Cat. No. CDB-H82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-CD79B (Polatuzumab) Humanized Antibody with a linear range of 0.1-2 ng/mL (Routinely tested).

CDB-C52H3-MALS-HPLC
Cynomolgus CD79B, His Tag (Cat. No. ) MALS images

The purity of Cynomolgus CD79B, His Tag (Cat. No. CDB-C52H3) is more than 90% and the molecular weight of this protein is around 20-40 kDa verified by SEC-MALS.

  • Background
    B-cell antigen receptor complex-associated protein beta chain (CD79b) is also known as B-cell-specific glycoprotein B29, Ig-beta,Immunoglobulin-associated B29 protein, B29 and IGB, which is a single-pass type I membrane protein containing one Ig-like V-type ( immunoglobulin-like ) domain and one ITAM domain.CD79b is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR).CD79b can enhance phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Defects in CD79b are the cause of agammaglobulinemia type 6 (AGM6) that is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Synonym Name

CD79b,B29,IGB,Ig-beta

Background

B-cell antigen receptor complex-associated protein beta chain (CD79b) is also known as B-cell-specific glycoprotein B29, Ig-beta,Immunoglobulin-associated B29 protein, B29 and IGB, which is a single-pass type I membrane protein containing one Ig-like V-type ( immunoglobulin-like ) domain and one ITAM domain.CD79b is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR).CD79b can enhance phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Defects in CD79b are the cause of agammaglobulinemia type 6 (AGM6) that is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Polatuzumab vedotin RO-5541077-000; FCU-2711; DCDS-4501A; RG-7596; RO-5541077 Approved Seattle Genetics Inc, Genentech Inc Polivy United States Lymphoma, Large B-Cell, Diffuse Genentech Inc 2019-06-10 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
TolDCB29 Phase 2 Clinical Umc Utrecht Arthritis, Rheumatoid Details
CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR CD19/79b Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Leukemia, B-Cell Details
CD79b-19 CAR T Cells Therapy (Massachusetts General Hospital) Massachusetts General Hospital Details
Iladatuzumab vedotin DCDS-0780A; RO-7032005 Phase 1 Clinical F. Hoffmann-La Roche Ltd Lymphoma, Non-Hodgkin Details
CD79b CAR-T cell therapy (Yake Biotechnology) Phase 1 Clinical Zhejiang University Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Biphenotypic, Acute Details
PRV-3279 HDM-3002; MGD-010; PRV-3279; CD32BxCD79B Phase 2 Clinical Macrogenics Inc Drug-Related Side Effects and Adverse Reactions; Lupus Erythematosus, Systemic Details
Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy(MD Anderson Cancer Center) JV-213 Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Lymphoma, B-Cell; Lymphoma Details
NBT-508 Phase 1 Clinical Newbio Therapeutics Inc Lymphoma, B-Cell; Lymphoma, Non-Hodgkin Details
SHR-A1912 SHR-A1912 Phase 2 Clinical Shanghai Hengrui Pharmaceutical Co Ltd Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message